Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind, Placebo Controlled Phase II / III Study to Assess Safety, Immunogenicity and Efficacy of Twice Dosing of Intramuscular AG0302-COVID19 (2mg) in Healthy Adults

NCT04655625 is registered in ClinicalTrials.gov with AnGes, Inc. as lead sponsor.

NCT NCT04655625
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04655625 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind, Placebo Controlled Phase II / III Study to Assess Safety, Immunogenicity and Efficacy of Twice Dosing of Intramuscular AG0302-COVID19 (2mg) in Healthy Adults
Lead sponsor
AnGes, Inc.
Phase
Phase 2/3
Overall status
Completed
Start date
November 23, 2020
Completion date
February 1, 2022
Enrollment
500 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19